Latest Schedule 13G passive stakes

Canadian Imperial Bank of Commerce has disclosed beneficial ownership of 7.3% of DraftKings Inc. common stock as of June 30, 2026.

A filing reveals Ayrton Capital LLC, Alto Opportunity Master Fund, SPC, and Waqas Khatri collectively hold a 1.59% stake in GeoVax Labs, Inc. through warrants.

Ayrton Capital LLC, along with its associated entities, has disclosed an 8.14% ownership stake in ESS Tech, Inc., primarily through common stock and exercisable warrants.

BNP Paribas SA has disclosed beneficial ownership of 15,305,255 shares, representing 8.87% of Krispy Kreme Inc.'s common stock, as of June 30, 2026.

Ayrton Capital LLC, along with Alto Opportunity Master Fund and Waqas Khatri, has reported beneficial ownership of 2,087,905 shares, representing 2.12% of Merlin, Inc.'s common stock.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 5,909,184 shares, representing 9.7% of Mirum Pharmaceuticals, Inc.'s common stock, as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 5,909,184 shares, representing 9.7% of Mirum Pharmaceuticals, Inc.'s common stock, as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Forte Biosciences, Inc., reporting a 9.3% stake as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Forte Biosciences, Inc., reporting a 9.3% stake as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 1,359,514 shares, representing 6.9% of the outstanding common stock of Assembly Biosciences, Inc.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 1,359,514 shares, representing 6.9% of the outstanding common stock of Assembly Biosciences, Inc.

Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of Tarsus Pharmaceuticals, Inc. common stock to 6.5%.

Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of Tarsus Pharmaceuticals, Inc. common stock to 6.5%.

Ayrton Capital LLC, along with its affiliates, has reported beneficial ownership of 5,319,149 shares of Fingermotion Inc. common stock, representing 7.99% of the class.

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 7.3% of Dyne Therapeutics Inc.'s common stock as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 7.3% of Dyne Therapeutics Inc.'s common stock as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Protara Therapeutics, Inc., reporting a 8.4% stake as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Protara Therapeutics, Inc., reporting a 8.4% stake as of June 30, 2026.

Canadian Imperial Bank of Commerce has updated its beneficial ownership filing for Flutter Entertainment plc, now holding 7.3% of the common stock.

Canadian Imperial Bank of Commerce has updated its beneficial ownership filing for Flutter Entertainment plc, now holding 7.3% of the common stock.

Janus Henderson Group Ltd. has filed a Schedule 13G, reporting beneficial ownership of 3,587,806 shares, representing 9.7% of Ziff Davis, Inc.'s common stock.

Janus Henderson Group Ltd. has filed a Schedule 13G, reporting beneficial ownership of 3,587,806 shares, representing 9.7% of Ziff Davis, Inc.'s common stock.

Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of ICU Medical, Inc. common stock to 11.1%.

Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of ICU Medical, Inc. common stock to 11.1%.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9,783,192 shares, representing 14.0% of Immix Biopharma, Inc.'s common stock, through various asset managers.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9,783,192 shares, representing 14.0% of Immix Biopharma, Inc.'s common stock, through various asset managers.

Janus Henderson Group Ltd. has updated its Schedule 13G filing to report a 0.3% beneficial ownership stake in Janux Therapeutics, Inc., indicating no change in control or significant strategic involvement.

Janus Henderson Group Ltd. has updated its Schedule 13G filing to report a 0.3% beneficial ownership stake in Janux Therapeutics, Inc., indicating no change in control or significant strategic involvement.

Janus Henderson Group Ltd. has filed a Schedule 13G, disclosing a beneficial ownership of 3.8% in Flex Ltd. ordinary shares as of June 30, 2026.

Janus Henderson Group Ltd. has filed a Schedule 13G, disclosing a beneficial ownership of 3.8% in Flex Ltd. ordinary shares as of June 30, 2026.